Find every page on the Lupus Research Alliance website in one place. Pages are grouped by section, followed by all funded research grants listed A to Z.
Jump to: Website Pages | Funded Research Grants
Website Pages
- About Our Research
- Accessibility
- Affiliates
- Combined Federal Campaign
- Dedication Wall
- Donor-Advised Fund (DAF)
- For Researchers
- In the News
- IRA Rollover
- Legacy Giving
- Logo and Resources Library
- Lupus Industry Council
- Lupus Landmark Study
- Lupus Landmark Study Submission
- Lupus Ventures
- Make a Donation with Crypto Currency
- Make a Gift of Stock
- Past Research Partnerships
- Payroll Deduction
- Robert Wood “Woody” Johnson IV
- Social Media Toolkit
- Submit Your Image & Message of Hope
- Webinars
- Sign Up for Updates
- Ways to Give
- Research
- Careers
- Who We Are
- About Lupus
- En Español
- Ways to Get Involved
- Research and Clinical Trials
- Disclaimer
- Privacy Policy
- Terms of Use
Funded Research Grants
Browse the research projects funded by the Lupus Research Alliance, listed A to Z by project title. You can also browse grants by award type on the Funded Research page.
Jump to: 0-9 | A | B | C | D | E | F | G | H | I | L | M | N | O | P | R | S | T | U | V
0-9
- 2021 Empowering Lupus Research Administrative Supplement
- 2022 Empowering Lupus Research Administrative Supplement
- 2023 Empowering Lupus Research Administrative Supplement
- 2024 Empowering Lupus Research Administrative Supplement
- 2025 Empowering Lupus Research Administrative Supplement
- 3D and single-cell epigenome technologies for autoimmune disease
A
- ACCELERATE
- Acquired immunologic genetic variation in lupus pathogenesis and heterogeneity
- Activation of iRhom2/ADAM17/HB-EGF/EGFR pathway in immune complex nephritis
- Age-associated B cells in autoimmune lupus
- Aggregated MAVS as a disease mechanism in SLE
- ALCAM in Lupus
- Allogenic BAFF CAR-NK Cell Therapy for Lupus
- Alteration of epigenetic programs of HSPC underlies the chronic activation of innate cells in SLE
- Altered renal circadian rhythm in SLE nephritis
- Analysis of antigen specific T cells in response to immune therapies in MS and T1D
- Anti-BDCA 2-targeted therapy for SLE
- Anti-CD71 immunotherapy to restore T cell homeostasis in autoimmunity
- Anti-commensal bacteria reactivity of VH4-34-encoded IgG antibodies in SLE
- Assessing lupus: developing a novel outcome approach for clinical trials
- Attacking the source: targeting plasma cell survival in lupus
- Autoantibodies and prolactin participate in a positive feedback loop
- Autophagy components and B cell activation during SLE
B
- B cell histone modifications and non-coding RNA as targets in lupus therapy
- B cell-intrinsic cytokine reg of spontaneous germinal ctr formation in SLE
- B-cell control point dysregulation in African Americans in SLE
- Bacterial amyloids from biofilms break tolerance in lupus
- Better days ahead: Improving renal repair after LN flare
- Beyond serology: Improving the prediction and treatment of lupus with single cell Omics
- Biological role of FCRL molecules in SLE pathogenesis
- Biomarker identification in SLE identified via microbiome-host interactions
- Biomaterial Models of Health Disparity in Lupus: Characterization of Ancestral Differences in Monocyte-Mediated Vascular Inflammation
- Blockade of Human CD21 with a Humanized Blocking Antibody
- Bone marrow stem cell niche dysfunction in human SLE
- Bradykinins in lupus
- BRISC DUB activity as a novel target for lupus
C
- Candidate pathobiont in lupus: genomic variation and pathogenesis
- Cathepsin S inhibitor-modified Treg cells mitigate murine SLE
- CD19-targeted cytotoxic T cells for lupus therapy
- CD244 targeting therapeutics in SLE
- CD4 T cell metabolism in SLE: characterization and target identification
- cGAMP as an immune transmitter of the interferon response
- Characterization and function of CD4 T cell subsets in lupus
- Characterization of chemokine producing effector B cells in SLE
- Characterization of STING SAVI gain of function mutations in mice
- Circadian dysregulation of immune function in SLE
- Clinical applications of urine proteomics to lupus nephritis
- COMET common mechanisms in autoimmunity
- Comprehensive multiomic analysis of the basis for cardiovascular risk in rheumatic disease
- Contribution of dysregulated granulopoiesis to SLE pathogenesis
- The contribution of epigenetics to SLE phenotype and outcome
- Correlative Biomarkers in the REACT-01 Pediatric Lupus CD19 CAR Trial
- The CR2:C3d receptor: ligand interaction as a therapeutic target in lupus
- Cross sectional and longitudinal studies of immune complexes in SLE
- Cutaneous and systemic lupus induced by UVB
- The cyclic GAMP pathway in SLE
- The cyclic GAMP pathway in SLE
- Cytokine immunoregulatory strategy to target SLE autoreactive B cells
D
- Deciphering the role of Epstein-Barr virus in SLE pathogenesis
- Defining factors that control the initial break in tolerance in lupus
- Defining fibroblast heterogeneity and its association with kidney function loss in lupus nephritis
- Defining Lupus Immunologic Variation in Effective Response
- Defining new targets in lupus through identification of non-coding SNPs
- Defining the determinants of lupus progression and cancerous transformation
- Development of cell-based therapies targeting DNA-reactive B cells in SLE
- Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling
- Dissecting molecular heterogeneity of SLE patient treatment response
- Dissecting phenotypic heterogeneity in endosomal TLR-driven autoimmunity using human UNC93B1 allelic variants
- Dissecting the effector function of pathogenic Tfh cells in human lupus
- Dissecting the genetics and host interactions of EBV-related autoimmunity
- Dissecting the immune landscape in lupus nephritis
- Dissecting the Origins, Specificities, and Helper Functions of T Cells in SLE
- Dissecting the Transition from Autoreactivity to Disease in Lupus Nephritis
- Diversity of anti-NMDA receptor autoantibodies in lupus patients
- DNA- and RNA-associated autoantigens in the activation of human B cells
- Dock2-mediated T cell migration as a targetable shared mechanism in autoimmunity
- Dual reactive B cells in murine and human SLE
- Dynamic regulation of signaling pathways in SLE
- Dysfunctional skin and bone loss in lupus
- Dysfunctional Tregs in lupus
- Dysregulation of alternative splicing in B cells and its role in SLE heterogeneity
E
- ELUCIDATE – Epigenetics; lupus urine cells in decoding APOL1 transmutation effect
- Elucidation of Retroelement-induced autoimmune responses in Systemic Lupus Erythematosus
- Engineered immunological niche to monitor lupus nephritis
- Epigenetic regulation of Il2 by ATF7ip – implications for SLE
- Epigenetic regulation of pathogenic B cells in SLE
- Epigenome profiling in human SLE
- Erythroid mitochondrial dysfunction in lupus pathogenesis
- Establishing the role of apoptosis and mtDNA in the pathobiology of lupus
- Estrogen-dependent microRNAs as potential targets for the treatment of SLE
- Examining the role of T cell exhaustion in lupus pathogenesis
- Exercise and muscle biology in systemic lupus erythematosus
- Exploring the Impact of Viral Infections on Lupus Development and Heterogeneity
- Exploring the role of interferon kappa in SLE pathogenesis
F
- “Failure to Appropriately Digest” as a new model of lupus pathogenesis
- Ferroptosis as a novel driver of inflammation in lupus nephritis
- Finding druggable pathways affected by the R90H-NCF1 SLE risk variants
- A free website for discovering non-coding lupus-associated variant function
- Function of SLE-related regulatory regions of human A20/TNFAIP3 gene
- Functional Genomics of Tfh Cell Metabolism and Lupus Pathogenesis
G
- Genetically engineering regulatory T cells to treat SLE
- GILZ: glucocorticoid mediator, B cell regulator, and lupus target
- Glycans and glycosylation defects as novel targets in lupus
- GMP-Ready Smith-Specific Regulatory T Cell Therapy to Treat Lupus Nephritis
H
- Hes1 as a novel regulator of the type I interferon pathway in SLE
- High through-put screening to repurpose drugs for lupus therapies
- High-Dimensional Imaging to Define Prognostic States in H&E Stained LN Biopsies
I
- Identification of lupus causal variants at 8p23.1 by mapping 3D genome
- Identification of new genes that restrict TLR7 responses to self nucleic acids
- Identification of pathogenic pathways through genomic engineering to identify shared genetic effects on people with T1D, SLE, and MS
- Identifying and targeting novel IFN-I regulators in pDCs for Lupus therapy
- Identifying functional variants that underlie SLE susceptibility
- Identifying Genetic and Immunological Determinants of Childhood Lupus Nephritis
- Identifying the mechanism of virus-induced lupus
- Identifying the role of CD96hi CD4+ T-cells in SLE
- IDO2, a novel therapeutic target for the treatment of lupus
- IgA-containing immune complexes in SLE
- IgG glycans, Fcgrs and renal elements dictate antibody pathogenicity in SLE
- IL-2 and IL-33 as therapeutic agents for lupus nephritis
- Immune reprogramming in Systemic Lupus Erythematosus following CD19 CAR T cell treatment
- Immunologic mechanisms for heterogeneity of cutaneous lupus erythematosus
- Immunometabolic & Mitochondrial Regulation of Epigenetics in Lupus
- The immunometabolite Itaconate as a novel driver of TLR7-mediated Systemic Lupus Erythematosus (SLE)
- Immunoproteasome selective inhibitors for lupus treatment
- Immunoregulatory mechanisms in systemic lupus
- Immunotargeting of T follicular helper (Tfh) cells for SLE treatment
- Impact of a Lupus-Associated PRKG1 Variant on Type I Interferons and Immune Dysregulation
- Impact of CD19-targeted CAR T cell therapy on B cell tolerance in SLE
- The impact of risk-associated genes on a novel injury-associated monocyte subset in lupus nephritis
- Impact of Transcriptional Regulators in Peripheral T Helper Cells (Tph) in Lupus
- Impaired mitochondrial clearance in systemic lupus erythematosus
- In situ adaptive immunity in lupus tubulointerstitial inflammation
- Inflammation, brain injury and trajectories of cognitive function in childhood-onset lupus
- Influence of BANK1 in the in vivo development of lupus
- Inhibition of IL-6 trans-signaling in SLE
- Innate immune cell mechanisms controlling inflammation in Systemic Lupus Erythematosus
- Insights into lupus heterogeneity by single-cell profiling of B cell activation
- Integrated analysis of chronic pain phenotypes and predictive biomarkers in SLE
- Integrins control the trafficking of autoantigens in B cells
- Intrinsic B cell epigenetic mediators as therapeutic targets in lupus
- Investigating the mechanisms of lupus-associated CNS dysfunction
- Investigating the role of IL-12 in Lupus
- Investigating the role of SLE serum factors in neonatal lupus cardiac fibrosis
- IRF1 decoy treatment
- Iron and ER stress in lupus nephritis
L
- Learning from viruses how to suppress type I interferons to cure lupus
- Linking ABIN-1 to SLE susceptibility
- Linking multiple disease compartments in T1D and multiple sclerosis
- Linking the microbiome and the B cell repertoire to lupus nephritis
- Local factors contributing to pathogenesis of proliferative lupus nephritis
- Longitudinal systemic and organ-specific heterogeneity in lupus
- Lupus in rural Georgia: investigating research barriers and environmental risk factors
- Lymphatic regulation and photosensitivity
M
- Machine learning based predictive models for systemic lupus erythematosus diagnosis and prevention
- Mammalian free glycan, glycocalyx and anti-glycan antibody in lupus
- Mechanisms and consequences of HDL small RNA communication in SLE
- Mechanisms for B cell tolerance following deep B cell depletion
- Mechanisms for human TLR8 induced placental injury
- Mechanisms linking the cell death machinery to TLR7 immunity in lupus
- Mechanisms of B Cell Polyreactivity in Autoimmunity: Toward Precision Immunotherapy
- Mechanisms of SCARF1 in regulating SLE
- Mechanisms of the autoimmune germinal center response in SLE
- Mechanisms of vascular injury and dysfunction in pediatric lupus
- Mechanistic Studies of CART Cell-Induced B Cell Depletion in SLE
- Metabolic networks and unbiased genetic screens to identify targets for SLE
- Metabolism of effector T cells as a target in SLE
- The microbiome and SLE
- Mitochondria, caspases and type I interferons in autoimmunity
- Mitochondrial autophagy in the control of systemic autoimmunity
- Modeling cognitive impairment in patients with systemic lupus erythematosus
- Molecular basis and novel therapy of systemic lupus-associated thrombosis
- Monitoring CD4+ T-cell responses in T1D, MS and SLE
- Multi-level biomarkers for psychiatric disorders in pediatric lupus
- Multimodal Nanobody Immunotherapy for SLE
- A multiomic approach to unravel immunology behind pregnancy complications in SLE
- Multiplexed single-cell imaging in pediatric lupus nephritis
N
- Neural Mechanisms of Whole-Health Lifestyle Strategies for Lupus
- Neutrophil elastase as a therapeutic target in lupus
- Neutrophil homeostasis through ginger supplementation in SLE
- Neutrophil migrasomes in Antiphospholipid Syndrome
- New drug targets for lupus through mechanistic modeling of multi-OMICs data
- New mechanisms for thrombosis and atherosclerosis in SLE and APS
- New molecular pathways leading to IRF5-mediated SLE
- New targets for treatment of glucocorticoid-resistant lupus
- The NLRP1 inflammasome as a driver of systemic lupus erythematosus pathogenesis
- Non-canonical autophagy, phagocytosis, and SLE
- Noninvasive imaging of lupus nephritis disease activity
- A novel approach for treating lupus by inhibiting Fli1 transcription factor
- A Novel CAR T Therapy for Selective Depletion of Autoimmune B cell in Lupus
- A Novel CART Cell Selectively Targeting Age-Associated B Cells to Treat Lupus
- Novel insights into cerebral lupus
- A novel target for neutrophil NETosis in lupus skin inflammation
- A novel therapeutic approach for SLE
- Novel treatments for lupus nephritis
- NR4A family as markers and mediators of B cell tolerance across autoimmune diseases: from antigen discovery to treatment
O
- Optimization of glucocorticoid use in lupus nephritis
- Optimized CAR-T Therapy for Lupus
- Origin, regulation and therapeutic targeting of extracellular DNA
- OX40L Targeted Chimeric Antigen Receptor (CAR) Tregs for SLE
- The OX40L-OX40 axis in lupus pathogenesis
- Oxidized mitochondrial DNA employs APEX1 in neutrophils to control lupus
P
- PARP7 as a New Negative Feedback Regulator of Type I Interferon Signaling
- Pathogenesis of chronic cutaneous lupus erythematosus
- Pesticides and chemical exposures, DNA methylation, and SLE phenotypes
- Phosphatase-activating antibody for cutaneous lupus therapy
- Piezo1 in Lupus Associated Cardiovascular Disease and Cognitive Impairment
- PLK1, a potential novel therapeutic target for lupus
- Precision Targeting of Lupus IGHV4-34+ Pathogenic B Cells with CAR T Cells
- Predicting response and non-response to therapy in SLE
- Probing autoreactive T cells across tissues in SLE
- Protein S: at the crossroads of thrombosis and inflammation in SLE
- PTPN22 Function in Human B Cells and Inhibition to Reset Tolerance in SLE
- Ptprz: A therapeutic target for Lupus Nephritis
R
- A Randomized, Double-Blind, Placebo-Controlled Trial of Quinacrine in Patients with Cutaneous Lupus
- Redesigning Dnase1L3 for the treatment of systemic lupus erythematosus
- Reframing the modulation of B cell signaling inhibitors in SLE
- Regulation of CD11c+Tbet+ B cells in lupus
- Regulation of SLE through SOCS1 mimetic peptides
- Regulation of T follicular helper cells in SLE by E3 ubiquitin ligase Cbl-b
- Relieving ER stress in lupus neutrophils
- Repopulation of tolerogenic B cells post B cell depletion therapy in lupus
- Restoration of Immune Cell Homeostasis in Tissue via CD19 CAR-T Cell Mediated B Cell Clearance in SLE
- RIG-I regulation of interferon signature in SLE
- Risk factors and outcomes of cerebrovascular accidents in childhood lupus
- A role for diet-sensitive gut commensals in systemic autoimmunity
- Role for SHP2 as a therapeutic target for systemic lupus erythematosus
- Role of B cell activation through toll-like receptors in systemic lupus erythematosus
- The role of bacterial infections in the pathogenesis of lupus
- The role of immune complexes and BAFF in promoting atherosclerosis in lupus
- Role of infection in obstetric antiphospholipid syndrome
- Role of intestinal host-microbe interactions in lupus pathogenesis
- The role of microglial subsets in driving neuropsychiatric symptoms of SLE
- Role of novel metabolite-receptor pathway in protection from lupus
- The role of polyamine catabolism in the development of lupus
- Role of the BAFF receptor BCMA to control B cell homeostasis and tolerance
- The role of the long non-coding RNA lincRNA-Eps in lupus
- Role of Tim-1 in kidneys during lupus
- The role of TLR8 in lupus nephritis
- Roles of the cGAS pathway in lupus
- The roles of the individual elements of the BAFF axis in murine SLE
S
- S100A4 in Lupus Nephritis
- Sensitive and Bispecific Chimeric TCR for SLE Therapy
- Serum Analytes Differentiate Between SLE Patients With and Without CI
- Sex and microbiota influence on immunoregulation and disease in BWF1 mice
- Sex disparity in lupus is driven by putative X-linked genes
- Sex hormones, dendritic cells, and the IFN signature in lupus
- SGLT2 inhibition as a novel treatment for lupus nephritis
- Shining a light on the drivers of photosensitivity in systemic lupus
- Single cell detection of IFN signaling in lupus patients
- Single-cell genomics dissection of common immune networks driving autoimmunity
- A Small Molecule Strategy to Safely Mimic Glucocorticoids by Enhancing GILZ
- Small Molecule Targeting ITGAM in Lupus
- sOX40 and sOX40L: Genetically motivated biomarkers with prognostic and predictive potential in SLE
- Systematic dissection of lupus non-coding risk variants in primary B cells
- Systemic effect of combined microbiome-derived mediators on lupus
T
- Targeted regulatory T cells (Tregs) to treat lupus nephritis
- Targeting a dendritic cell-stromal axis in lupus
- Targeting a novel population of innate-like CD8+ Treg in lupus
- Targeting anti-ERV B cells using CAAR T cells
- Targeting autoreactive B cells to prevent thrombosis and fetal loss in SLE
- Targeting CXCR6+ T cell recruitment and memory in cutaneous lupus
- Targeting DNA polynucleotides in lupus
- Targeting endogenous glomerular repair in lupus nephritis
- Targeting EZH2 in lupus
- Targeting Follicular Helper CD4 T cells in SLE
- Targeting follicular helper T cell metabolism in lupus
- Targeting follicular helper T cells in lupus
- Targeting Hippo signaling to downregulate IFN production in SLE
- Targeting IL-10 producing B cells in SLE
- Targeting immunometabolism and co-stimulation in combination therapies in lupus
- Targeting interferogenic signals regulated by SLE risk gene PTPN22
- Targeting interferon-stimulated transcription as a novel lupus therapy
- Targeting mTORC2 for lupus treatment
- Targeting NETs in Obstetric APS
- Targeting nicotinic receptors to reduce inflammation associated with SLE
- Targeting pathogenic endothelial dysfunction in lupus nephritis
- Targeting pathogenic endothelial dysfunction in systemic lupus erythematosus: translation to clinical trials
- Targeting peripheral T cell-B cell interactions in SLE
- Targeting the CXCR3 chemokine axis in cutaneous lupus
- Targeting the inactive X chromosome in lupus
- Targeting the inactive X for correcting dosage imbalances in lupus
- Targeting the proteoglycan switch for lupus therapy
- Targeting the VISTA pathway prevents fatal systemic lupus
- Targeting type II NKT cells for a novel therapeutic in lupus
- Targeting VISTA in lupus skin disease and photosensitivity
- Therapeutic inhibitors of antigen presentation pathways in SLE
- Therapeutic potential of sialylated IgG Fc in SLE
- Therapeutic selective targeting of BAFF receptors
- Therapeutic targeting of FcgRIIb on B cells in SLE
- Tissue sodium in autoimmune disease
- Tissue-adaptive effector cells promote tissue damage in SLE
- TLR9 regulates Axl dependent migration of autoreactive B cells
- Tolerogenic dendritic cells in human lupus
- Towards understanding the role of NCF2 in SLE
- A transcriptional focus on new cells and pathways in SLE
- Transcutaneous Vagus Nerve Stimulation in SLE (TvSSLE)
- TREM-1 in lupus nephritis
- Turning sweet on autoimmunity: impact of glycans in Systemic Lupus Erythematosus pathogenesis and treatment
- TWEAK/Fn14 pathway in the pathogenesis & treatment of neuropsychiatric SLE
U
- Uncovering the Molecular Signatures of Treatment Response in LN
- Understanding common tissue tolerance mechanisms in autoimmunity
- Understanding role of B cells in the pathogenesis of Type 1 Diabetes and Multiple Sclerosis
- Understanding the Menopausal Transition in SLE: Symptom Burden and Therapeutic Implications
- Understanding the MoA of low dose IL-2 as a potential therapy for SLE
- Understanding the pathway regulated by the lupus susceptibility gene Ets1
- Unexpected role(s) for IRF5 risk variants in SLE pathogenesis
- Untangling Lupus Through Integrative Multi-Omics Approaches (ULTIMA)
- Urinomics as a guide to the renal immune landscape in SLE